Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database.
Concurrent
Immunotherapy
NSCLC
Oligometastases
Radiotherapy
Stereotactic
Targeted therapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
06 Jan 2021
06 Jan 2021
Historique:
received:
28
10
2020
accepted:
06
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
4
9
2021
Statut:
epublish
Résumé
Metastasis directed treatment (MDT) is increasingly performed with the attempt to improve outcome in non-small cell lung cancer (NSCLC) patients receiving targeted- or immunotherapy (TT/IT). This study aimed to assess the safety and efficacy of metastasis directed stereotactic radiotherapy (SRT) concurrent to TT/IT in NSCLC patients. A retrospective multicenter cohort of stage IV NSCLC patients treated with TT/IT and concurrent (≤ 30 days) MDT was established. 56% and 44% of patients were treated for oligoprogressive disease (OPD) or polyprogressive disease (PPD) under TT/IT, polyprogressive respectively. Survival was analyzed using Kaplan-Meier and log rank testing. Toxicity was scored using CTCAE v4.03 criteria. Predictive factors for overall survival (OS), progression free survival (PFS) and time to therapy switch (TTS) were analyzed with uni- and multivariate analysis. MDT of 192 lesions in 108 patients was performed between 07/2009 and 05/2018. Concurrent TT/IT consisted of EGFR/ALK-inhibitors (60%), immune checkpoint inhibitors (31%), VEGF-antibodies (8%) and PARP-inhibitors (1%). 2y-OS was 51% for OPD and 25% for PPD. After 1 year, 58% of OPD and 39% of PPD patients remained on the same TT/IT. Second progression after MDT was oligometastatic (≤ 5 lesions) in 59% of patients. Severe acute and late toxicity was observed in 5.5% and 1.9% of patients. In multivariate analysis, OS was influenced by the clinical metastatic status (p = 0.002, HR 2.03, 95% CI 1.30-3.17). PFS was better in patients receiving their first line of systemic treatment (p = 0.033, HR 1.7, 95% CI 1.05-2.77) and with only one metastases-affected organ (p = 0.023, HR 2.04, 95% CI 1.10-3.79). TTS was 6 months longer in patients with one metastases-affected organ (p = 0.031, HR 2.53, 95% CI 1.09-5.89). Death was never therapy-related. Metastases-directed SRT in NSCLC patients can be safely performed concurrent to TT/IT with a low risk of severe toxicity. To find the ideal sequence of the available multidisciplinary treatment options for NSCLC and determine what patients will benefit most, a further evaluated in a broader context within prospective clinical trials is needed continuation of TT/IT beyond progression combined with MDT for progressive lesions appears promising but requires prospective evaluation. retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Metastasis directed treatment (MDT) is increasingly performed with the attempt to improve outcome in non-small cell lung cancer (NSCLC) patients receiving targeted- or immunotherapy (TT/IT). This study aimed to assess the safety and efficacy of metastasis directed stereotactic radiotherapy (SRT) concurrent to TT/IT in NSCLC patients.
METHODS
METHODS
A retrospective multicenter cohort of stage IV NSCLC patients treated with TT/IT and concurrent (≤ 30 days) MDT was established. 56% and 44% of patients were treated for oligoprogressive disease (OPD) or polyprogressive disease (PPD) under TT/IT, polyprogressive respectively. Survival was analyzed using Kaplan-Meier and log rank testing. Toxicity was scored using CTCAE v4.03 criteria. Predictive factors for overall survival (OS), progression free survival (PFS) and time to therapy switch (TTS) were analyzed with uni- and multivariate analysis.
RESULTS
RESULTS
MDT of 192 lesions in 108 patients was performed between 07/2009 and 05/2018. Concurrent TT/IT consisted of EGFR/ALK-inhibitors (60%), immune checkpoint inhibitors (31%), VEGF-antibodies (8%) and PARP-inhibitors (1%). 2y-OS was 51% for OPD and 25% for PPD. After 1 year, 58% of OPD and 39% of PPD patients remained on the same TT/IT. Second progression after MDT was oligometastatic (≤ 5 lesions) in 59% of patients. Severe acute and late toxicity was observed in 5.5% and 1.9% of patients. In multivariate analysis, OS was influenced by the clinical metastatic status (p = 0.002, HR 2.03, 95% CI 1.30-3.17). PFS was better in patients receiving their first line of systemic treatment (p = 0.033, HR 1.7, 95% CI 1.05-2.77) and with only one metastases-affected organ (p = 0.023, HR 2.04, 95% CI 1.10-3.79). TTS was 6 months longer in patients with one metastases-affected organ (p = 0.031, HR 2.53, 95% CI 1.09-5.89). Death was never therapy-related.
CONCLUSIONS
CONCLUSIONS
Metastases-directed SRT in NSCLC patients can be safely performed concurrent to TT/IT with a low risk of severe toxicity. To find the ideal sequence of the available multidisciplinary treatment options for NSCLC and determine what patients will benefit most, a further evaluated in a broader context within prospective clinical trials is needed continuation of TT/IT beyond progression combined with MDT for progressive lesions appears promising but requires prospective evaluation.
TRIAL REGISTRATION
BACKGROUND
retrospectively registered.
Identifiants
pubmed: 33407611
doi: 10.1186/s13014-020-01730-0
pii: 10.1186/s13014-020-01730-0
pmc: PMC7788768
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Références
Crit Rev Oncol Hematol. 2017 Sep;117:38-47
pubmed: 28807234
J Thorac Oncol. 2012 Dec;7(12):1807-1814
pubmed: 23154552
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
J Thorac Oncol. 2015 Nov;10(11):1601-7
pubmed: 26313684
Int J Urol. 2017 May;24(5):361-366
pubmed: 28258623
Cancer Lett. 2015 Jan 1;356(1):82-90
pubmed: 24125863
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):892-8
pubmed: 24462383
JAMA Oncol. 2018 Jan 11;4(1):e173501
pubmed: 28973074
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Neuro Oncol. 2016 Aug;18(8):1043-65
pubmed: 27382120
Lung Cancer. 2019 Apr;130:149-155
pubmed: 30885336
Neuro Oncol. 2016 Mar;18(3):435-44
pubmed: 26385615
Nat Commun. 2018 May 4;9(1):1793
pubmed: 29728604
Lung Cancer. 2018 Oct;124:219-226
pubmed: 30268464
Radiat Oncol. 2019 Mar 13;14(1):44
pubmed: 30866974
Lung Cancer. 2013 Nov;82(2):197-203
pubmed: 24051084
Ann Transl Med. 2018 Jul;6(14):283
pubmed: 30105233
J Clin Oncol. 2017 Apr 1;35(10):1070-1077
pubmed: 28113019
J Thorac Oncol. 2017 Sep;12(9):1442-1445
pubmed: 28576747
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Clin Oncol. 2014 Dec 1;32(34):3824-30
pubmed: 25349291
J Thorac Oncol. 2013 Mar;8(3):346-51
pubmed: 23407558
Am Soc Clin Oncol Educ Book. 2017;37:607-618
pubmed: 28561721
Oncologist. 2016 Aug;21(8):964-73
pubmed: 27354669
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
Radiat Oncol. 2018 May 16;13(1):96
pubmed: 29769103
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
Clin Lung Cancer. 2019 Jan;20(1):43-47
pubmed: 30343004
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301